

Two β -lactamics resistance genes detection in nosocomial bacteria of veterinary interest

¹Arros M, ¹Jara MA, ²Mosnaim AD and ¹Navarro C*

¹Department of Animal Preventive Medicine. FAVET, Universidad de Chile

²Cellular and Molecular Pharmacology, Clinical Sciences, Psychiatry & Behavioral Science, Rosalind Franklin University of Medicine and Science, NY. USA

Corresponding author: canavarr@uchile.cl

Received on: 16/10/2019

Accepted on: 07/12/2019

Published on: 23/12/2019

ABSTRACT

Aim: The aim of this study was to analyze samples and identify the most frequent genes that conferred resistance to the beta-lactam antimicrobials (ampicillin and methicillin).

Method and Materials: Sixty-seven samples were collected between 2007 and 2008 from clinical veterinary centers of the University of Chile and analysed through a polymerase chain reaction (PCR) assay.

Results: Amplification by PCR detected DNA fragments from the blaTEM gene in Gram-negative and Gram-positive bacteria. Also the mecA gene was detected in Gram-positive bacteria.

Conclusion: These findings argue that a high number of bacteria express these genes, which should generate great concern to those responsible for the veterinary hospital locations of the University of Chile. Furthermore, as a preventive measure many efforts should be made in order to solve this problem.

Keywords: β -lactamics resistance, genes detection, nosocomial bacteria, polymerase chain reaction (PCR).

Cite This Article as: Arros M, Jara MA, Mosnaim AD and Navarro C (2019). Two β -lactamics resistance genes detection in nosocomial bacteria of veterinary interest. J. Vet. Res. Adv. 01(01): 01-27.

Introduction

The use of antimicrobials has had a high impact on medicine. Since the discovery of the first antibiotic (penicillin) and the first chemo-therapeutic molecules (sulfa), these drugs have been used to control infections, thanks to their ability to inhibit or destroy life-threatening bacteria. However, bacteria, through information contained in their genes, possess or have developed different resistance mechanisms against antimicrobials.

These mechanisms have limited the effect that antimicrobials produce on bacteria, becoming a very important challenge both for doctors who face complicated treatment diseases, and for pharmaceutical laboratories that must generate more efficient drugs.

The indiscriminate use of antibiotics has not only caused the selection of resistant bacteria in microbial populations, but also causes limitations in antimicrobial therapy. It is for this reason that since the discovery of the first mechanism of resistance to penicillins by Abraham and Chain in 1940, expert scientists have expressed their concern regarding the irrational use of antimicrobials, in order to try to mitigate the selective pressure that fosters the development of mechanisms

Copyright: Arros et al. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

of resistance and have the greatest amount of therapeutic resources to fight bacteria.

In the hospital enclosures the problem of resistance increases every year, due to the existence of nosocomial bacteria, which correspond to those that are acquired within a hospital premises and whose manifestation occurs 48-72 hours after the patient's admission, generating a nosocomial infection (WHO, 2003). These types of infections caused by ubiquitous, opportunistic and highly resistant bacteria have acquired great importance in medical practice and are those that especially affect the immuno-compromised patient, prototype in intensive care units. Thus, the above could explain its high transmission rate.

Nosocomial bacteria generate infections of high morbidity and mortality because they have multi-resistance phenotypes. That is, they resist or inhibit the action of two or more antimicrobials, so their treatment and control is very limited. Thus, they affect between 5 and 10% the evolution and recovery of the clinical pictures of hospitalized patients, generating longer residence times in hospital areas and higher treatment costs.

In this context, antimicrobials belonging to the β -lactam group have been limited in their activity in the treatment of infections due to the increase in resistant bacteria. These antimicrobials are indicated for the treatment of infections caused by susceptible microorganisms, becoming the group of antimicrobials most used in the treatment of infectious diseases, which translates into a major problem in both human public health and animal

health. In addition, it has been determined that the factors that have contributed to the increase in nosocomial infections in human medicine hospitals show similarities with those found in veterinary medicine.

Consequently, efforts have been directed to complement the epidemiological surveillance of antimicrobial resistance, using molecular diagnostic techniques, to develop new control strategies. Currently, a large number of very varied studies have been described in human medicine, unlike what happens in veterinary medicine within Chile.

According to the above, in this work and using the Polymerase Chain Reaction (PCR), two genes (*mecA* and *blaTEM*) involved in the resistance to methicillin and ampicillin antimicrobials were detected in bacteria described as nosocomial. This will allow us to make an approximation of the situation that these genes present in the hospital precincts of the University of Chile and a first approach to the topic in veterinary medicine within the country, in order to develop future epidemiological studies that determine the behavior of these genes in populations bacterial.

Nosocomial Infections

Epidemiological Importance

Infections have different etiological agents: bacteria, viruses, parasites and fungi. In the case of bacteria, they can be transmitted constantly between animals, without necessarily being a health risk. However, in the hospital environment, bacterial populations are established that coexist under a highly variable and

demanding environment, which exposes them to various stress situations, which as a selective pressure force, has been the fundamental cause in the appearance of highly bacterial strains resistant (Vali et al., 2008, Antonovics et al., 2017).

This situation generally occurs under an antimicrobial regimen or invasive procedures with the use of antiseptics for long periods of time. This favors the multiplication of those infectious bacteria, with the genetic-molecular potential to resist antimicrobial therapies, being able to generate serious infections that compromise the survival and recovery of patients due to the nature of the infectious process and its poor response to treatment (Stickler, 2002; Davies and Davies, 2010).

The acquisition of multi-resistant bacterial agents as commensals is the first stage in the pathogenesis of nosocomial infection. Within this, the host's immune system plays an essential role, as bacteria must not only use their energy to resist the action of antimicrobials, but also host-specific molecules (DHQP, 2001). Therefore, the acquisition of these infections occurs mainly in immuno-compromised individuals (Stickler, 2002; Peterson and Kaur, 2018).

The U.S. Center for Disease Prevention and Control defines nosocomial infection as an adverse reaction resulting from a systemic or localized condition due to the presence of an infectious agent or its toxin. There should be no evidence that the infectious agent was present or was being incubated before the patient entered the hospital (CDC, 2008),

To be classified as an infection, this condition must manifest itself as a clinical disease and not as a simple colonization, which means that microorganisms are present, but they do not exert adverse effects on the host. However, an asymptomatic patient can be considered infected if pathogenic microorganisms are found somewhere in the body that is normally sterile, such as cerebrospinal fluid or blood (Emori and Gaynes, 1993; Casadevall, 2017).

It has been described that more than 70% of the bacteria that cause nosocomial infections are resistant to one or more of the antibiotics commonly used in their treatment. These microorganisms are the cause of an increase in the costs of medical care and hospital stay (Muto et al., 2003) and can also be transmitted by patients to health care staff, visitors and the community after hospital discharge, with the possibility of causing serious diseases in the community (WHO, 2003; Rajab et al., 2015).

The incidence of nosocomial infections is very high in a large part of developing countries, due to lack of supervision, the few preventive practices of infections and the high population density that exists in some of the hospitals (Murni et al., 2013.; Haque et al., 2018). Some studies have indicated that nosocomial infections occur in 5% to 10% of all hospitalizations in Europe and North America, and in more than 40% of hospitalizations in different parts of Asia, Latin America and South Africa (Raka et al., 2006; Revelas, 2012). In turn, a prevalence survey conducted in 55 hospitals in 14 different countries showed that an average of 8.7% of

hospitalized patients present with nosocomial infections (WHO, 2003; Ginawi et al., 2014).

Nosocomial bacterial agents and clinical considerations

The bacteria that cause nosocomial infections have undergone major changes over time and initially, the predominant pathogens detected were mainly Gram positive. Then, with the introduction of antibiotics there was a decrease in these infections, becoming mostly produced by Gram negative bacteria (Alpuche and Daza, 2002). However, in some countries Gram pathogens positives predominate over 60% while Gram negatives do not reach 30% (Morfin et al., 2002; Mehrad et al., 2015).

The bacterial agents, described as nosocomial, more abundant -both in human medicine and in veterinary medicine- are the following: *Staphylococcus aureus* (*S. aureus*), *Pseudomonas aeruginosa* (*Ps. aeruginosa*), *Acinetobacter* spp; *Enterococcus faecium* (*E. faecium*), *Enterococcus faecalis* (*E. faecalis*) and other enterococci: *Enterobacter cloacae* (*E. cloacae*), *Klebsiella pneumonia* (*K. pneumonia*), *Serratia marcescens* (*S. marcescens*) and *Proteus* spp. (PAHO, 2005; Galler et al., 2018).

All the mentioned bacteria have clinical pictures described: pneumonia associated with mechanical ventilation, blood infections associated with intravenous catheters and urinary tract infections associated with urinary catheters (Rosenthal et al., 2006; Peleg et al., 2008). In addition to these, it has been determined that infections of surgically operated sites are also an

important cause of nosocomial infection, and have a high frequency in human hospitals (Guggenbichler et al., 2011; Murni et al., 2013.). In the case of veterinary medicine, publications are scarce, but studies reveal results similar to those of human medicine, mentioning urinary tract infections and surgical wound infections as the most important (Ogeer-Gyles et al., 2006; Peters et al., 2019).

In general, nosocomial bacteria are considered multiresistant microorganisms, that is, they are resistant to two or more antimicrobials. A large number of multiresistant organisms that have epidemiological importance are described. These include: Methicillin-resistant *S. aureus* (MRSA) and vancomycin-resistant enterococci (VRE), although their name suggests resistance to only one antimicrobial, they also have resistance to other antimicrobials, so their finding or detection should be a concern constant in hospitals and clinics (CDC, 2008; van Duin and Paterson, 2016).

Among other bacterial agents that have multiresistance characteristics are: Multiresistant *Streptococcus pneumoniae* (PMS) that resist the action of penicillins and a broad spectrum of antimicrobial agents such as: macrolides and fluroquinolones; some multiresistant Gram-negative bacilli (BGN-MR) especially producers of extended spectrum betalactamases (BLsEE) (Jacoby and Munoz-Price, 2005), and finally Vancomycin-resistant *S. aureus* (SARV) that have developed great concern in the medical practice (Pascual et al., 2001; Zhanel et al., 2001), since vancomycin is a backup

antimicrobial for the treatment of *Staphylococcus aureus* (CDC, 2008).

Thus, among the bacteria with greater clinical-epidemiological importance are the methicillin-resistant *Staphylococcus aureus* (MRSA) and some vancomycin-resistant *Enterococcus* (VRE), which have generated great concern in medical practice. Within *Enterococcus* spp., *E. faecalis* and *E. faecium*, both Gram-positive, are especially important (Boerlin et al., 2001; Faron et al., 2016). Finally, among Gram-negative bacteria, *Ps. aeruginosa* has unquestionably developed great importance, and in turn, Enterobacteria are still of interest (DHQP, 2001).

Considering that nosocomial bacteria are opportunistic, that infects and cause complications of existing pathological processes, they should be addressed strategically. Therefore, it is important that the necessary biosecurity measures are taken for the prevention and control of these bacteria. A fundamental step is to have rigorous control measures regarding the clinical use of antimicrobials and measures that prevent the transmission of pathogens that are already resistant (Alpuche and Daza, 2002; Alsan and Klompas, 2010).

Without a doubt, prevention is the most important factor in the control of these infections. In spite of the enormous effort made by the medical and healthcare team of the hospitals, to reduce the prevalence of nosocomial infections, it has been seen that they continue to manifest in hospitalized patients and that they can also affect the staff of the place. This has been reflected in the fact that many of the professionals who work in hospitals sometimes act as

vectors of the disease, spreading the infection (Saloojee and Steenhoff, 2001; Haque et al., 2018).

The measures established as part of a control program seek to limit the transmission of microorganisms among patients by means of : 1). proper hand washing practices, use of gloves and masks, 2). isolation strategies, 3). limit the risk of Endogenous infections minimizing invasive procedures and encouraging the appropriate use of antimicrobials and 4) monitoring infections, identifying outbreaks and controlling the responsible agents (Ducel et al., 2003; Mehta et al., 2014).

In general, the hospital medical and healthcare team is recommended to implement a cleaning protocol, considering the frequency of cleaning, types of disinfectants, hand washing practice and the use of aseptic techniques in the management of invasive devices. In addition, protection barriers must be established between animals, decrease hospitalization times and determine possible microorganism vectors (Johnson, 2002; Sydnor and Perl, 2011).

Bacterial resistance

Development and importance of resistance in nosocomial infections.

Historically, bacterial resistance to antimicrobials was defined as persistent bacterial infection, despite the administration of an adequate dose of a specific antimicrobial. Later, this definition was modified by relating resistance to antimicrobial concentration at the site of action. Thus, the resistance could be partial or relative. Bacterial resistance represents the ability of microorganisms to inhibit the action of

antimicrobials. Currently, a bacterium is considered resistant when the concentrations of an antimicrobial needed to inhibit its growth in vitro are greater than the concentrations reached in serum or tissues, measured by the minimum inhibitory concentration (MIC) (Sussmann et al., 2003; Fair and Tor, 2014).

The information that allows a bacterium to develop a resistance mechanism is found in its genetic material. The emergence and dissemination of resistance mechanisms is favored by the ability of bacteria to modify their genetic material or receiving genetic material horizontally from other bacteria (Sussmann et al., 2003; Bengtsson-Palme et al., 2018).

It is known that every resistance phenomenon has a genetic basis, either by mutations, by acquisition of resistance genes that are transferred between bacteria or by a combination of both mechanisms. Resistance genes may be present in pathogenic, commensal or zoonotic bacteria, but the incidence of these genes varies considerably between bacterial species and even among subspecies. For example, Gram-positive bacteria, except for staphylococci and enterococci, often lack the ability to acquire plasmids that contain resistance genes (R-plasmids) (EMEA, 1999). The presence of a resistance gene does not necessarily lead to treatment failure (Milatovic and Bravendy, 1987), since the level of expression can be low. Thus, the production of β -lactamase by a bacterium is known, but the development of resistance is dependent on the mode and level of expression of the responsible gene (Lui et al., 1992; Zeng and Lin, 2013)

The widespread use of antimicrobials, irrational and without justification, allows resistant strains of several bacterial species to emerge shortly after use (Cabrera et al., 2007; Prestinaci et al., 2015). According to Johnson (2002), nosocomial organisms in human hospitals and the pattern of antimicrobial resistance within these establishments change when the use of specific antibiotics is restricted. It is for this reason that it has become necessary to use antimicrobials with a greater criterion, which encompasses both the medical/professional experience, and the theoretical framework in each therapeutic alternative. At present, molecules as novel as moxifloxacin, extended spectrum cephalosporins, carbapenemic and monobactamic derivatives are ineffective when treating bacterial infections, especially nosocomial ones (DHQP, 2001; Cantón and Morosini, 2011)

Antimicrobial resistant microorganisms may also acquire resistance to other antimicrobials that share a mechanism of action. Such relationships, known as cross resistance, occur against agents that are closely related in their chemical formula, such as neomycin-kanamycin. There may also be cross resistance among unrelated chemicals (such as erythromycin-lincomycin). Cross resistance, together with the possibility of acquiring genetic material that confers resistance to more than one type of antimicrobial, enables the appearance of multiresistant bacteria, against which the amount of effective antimicrobials is reduced (Borneman, 2002; Munita and Arias, 2016).

Multiple antimicrobial resistance has been demonstrated in nosocomial bacteria in veterinary hospitals and is more frequent in patients who have previously been treated with such antibiotics. In hospitals, where the use of antimicrobials is common, bacteria with antibiotic resistance have a selective advantage compared to other bacterial populations. It is the wide application of antimicrobials in the practice of veterinary medicine, the use of antibiotics in agriculture (antibiotics such as avoparcin or tetracycline) and the use of antiseptics and disinfectants, which would cause this selective pressure on bacteria (Johnson, 2002; Li and Webster, 2018).

The development of bacterial resistance is based, mainly, on the prevalence of resistance genes in bacterial populations and the misuse of antimicrobials, which generate a selective pressure on bacteria with resistance phenotypes. That is, antimicrobial drugs do not generate resistance, but they do favor the survival of resistant microorganisms, by a natural selection process. Generally, this phenomenon occurs in developing countries, where not only antimicrobials are misused but frequently used insufficiently due to financial constraints (WHO, 2003).

Bacterial resistance phenomena not only threaten the success of new antibiotic treatments and the effectiveness of biosecurity measures, they also do so directly affecting the safety of various animal products. Cases of transmission to the human species have been described, from potentially dangerous bacteria, through food and

through direct contact (Duquette and Nuttall, 2004; Rousham et al., 2018).

Mechanisms for transferring genetic information between bacteria

In general, there are two different ways of acquiring resistance, intrinsic (vertical) and acquired. Intrinsic resistance to an antimicrobial in some species is of a natural nature, either because they lack the cellular mechanisms in which the drug exerts its action or because the bacterial cell wall is impervious to that drug (Peterson and Kaur, 2018).

Acquired resistance, on the other hand, can be caused by mutation or by the transfer of genetic material encoding resistance to a particular antimicrobial. Mutations can be transferred vertically to daughter cells, while horizontal transfer, which allows the transfer of genetic material between bacteria of the same or different species, occurs through the mechanisms of conjugation, transduction and transformation. Within these, conjugation is the most common form of transfer, and consists in the transfer of genetic material thanks to the presence of sexual pilis (Tsang, 2018).

Conjugation is a fundamental transfer system for prokaryotes, which allows the transfer of conjugative elements such as plasmids and transposons. These require complex groups of genes that encode the transfer system and subsequent establishment in the recipient cell of said elements. This phenomenon is based on the cellular recognition and establishment of a stable pairing, facilitated by specialized elements, within which a sexual pilus for Gram-negative bacteria and an

aggregating substance (SA) of a protein nature in Gram-positive are described. Once this mating is achieved, a conjugative pore is formed, through which single stranded DNA is transferred only or a nucleoproteic complex (relaxoma). The process ends with the synthesis of strands complementary to the single strand in the donor and recipient (Wilkins and Frost, 2002; Delavat et al., 2017).

The pilis recognize the recipient cell and establish contact by retraction, there are systems without this property, and like Gram-positives they need to collide to mate stably. The SA recognizes the lipoteic acid of the recipient thanks to the fact that it forms a film on the donor surface. In the process, a series of genetic entities can be transferred as conjugative and integron transposons (included in conjugative or mobilizable plasmids) and even the transfer of large genetic segments (Wilkins and Frost, 2002; Delavat et al., 2017).

The mobilizable elements only encode the genes of the relaxome and not those corresponding to the conjugative pore (transferoma), therefore, they must be mobilized together with other conjugative elements in the same event, taking advantage of the intercellular bridge generated by them (Salyers and Amabile-Cuevas, 1997; Guédon et al., 2017).

The conjugative transposons are self-transferable elements incorporated in the genome with unique characteristics in their cleavage and integration mechanisms, essential for transfer. Its cleavage (Xis) cuts each end of the element leaving coupling sequences, which covalently join to form a circular

intermediate (transferable intact or as a single-stranded structure), while integrase (int) cuts and incorporates the coupling sequences to the site white (Salyers and Amabile-Cuevas, 1997; Guédon et al., 2017). Integrons are mobile genetic units that have highly conserved sequences at their ends that embrace a variable region in which gene "cassettes" are inserted. At the 5' end, the DNA integrase is encoded, an enzyme responsible for the site-specific integration of this element in the bacterial DNA, determines according to its characteristics four classes of integrons (I-IV). At the 3' end the qacE gene or its defective variant qacEΔ1 is encoded. These elements are capable of incorporating several gene units and inducing their joint expression as a transcriptional unit (operon). The latter determines that the element has different lengths and code different phenotypes, according to the number and nature of the inserted genes (Stokes and Hall, 1989; Arkhipova and Yushenova, 2019).

Mechanism of resistance against antimicrobials

In relation to the mechanisms of resistance, from the molecular and biochemical point of view, at least four have been described (Sussmann et al., 2003; Nikaido, 2009) one bacterial strain being able to use one, several combined or all. These mechanisms are:

A) Inactivation of the drug: this resistance mechanism consists in the production of Enzymes that destroy the antimicrobial by hydrolysis, such as β -lactamases produced by a wide variety of Gram-negative and some Gram-positive bacteria such as staphylococci

and streptococci. On the other hand, some bacteria have the ability to produce enzymes that modify the structure of antimicrobials, such as the aminoglycoside modifying enzymes, which have been detected in Gram-negative bacilli of the enterobacteria group.

B) Alteration of the white site of the antimicrobial: this mechanism consists in the modification of the site of action of the drug, so that it is no longer significantly affected by the drug (ie. penicillin binding proteins [PBPs]), or, alternatively, the production of said molecule may be amplified to levels such that the dose is insufficient.

C) Active efflux of the drug: it is a special type of exclusion, in which the molecule that initially enters the bacterial cell, through the cell membrane, is transported back to the extracellular environment, thus preventing the molecule from reaching its action site. This mechanism has been described as responsible for tetracycline resistance among Gram-negative bacilli and also in Gram-positive cocci of the genus *Staphylococcus*.

D) Decrease in the entry of the drug into the bacteria: the bacterial cell can prevent an antimicrobial from reaching an adequate concentration at the site of action, preventing its entry into the intracellular environment, through three mechanisms: (1) Permeability of the outer membrane: clearly defined in Gram-negative microorganisms, which have an outer membrane that constitutes an intrinsic barrier to the penetration of some antimicrobial drugs. (2) Permeability of the inner membrane: another form of resistance of the bacteria consists of an energetic

modification that compromises the anionic transporter, which takes the antimicrobial into the cell. The presence of the lipid layer in the membrane acts as a resistance mechanism for hydrophobic drugs and (3) Porins: they are diffusion channels present in the outer membrane of Gram-positive bacteria. From the modification by mutation of these proteins a decrease in the passage of the antimicrobial is generated.

Antimicrobials

Antimicrobials are natural, semi-synthetic or synthetic chemicals that kill or slow the growth of microorganisms (CDC, 2008). Antibiotics (from Greek: anti, "against"; bios, "life") are chemical substances produced by different species of microorganisms (such as bacteria and fungi) or synthesized by laboratory methods, which suppress the growth of other microorganisms and may eventually destroy them. These compounds differ markedly from their physical, chemical and pharmacological properties, as well as in their mechanism of action and antimicrobial spectrum (McDonnell and Russell, 2001; Davies and Davies, 2010).

Mechanisms of action of antimicrobials

They can be basically classified into 5 types: (A) Inhibition of cell wall synthesis: the cell wall provides, among other things, protection against the great osmotic pressure inside the cell, so when it is inhibited or found defective, the cell will suffer lysis. Penicillins and cephalosporins they are antimicrobials that use this mechanism, being effective against Gram-positive bacteria due to the high osmotic pressure inside this type of bacteria and having a large

proportion of peptidoglycan in the cell wall, unlike Gram-negative bacteria that, in addition, if they have low osmotic pressure, they have wall structures that protect them from these antimicrobials. (B) Alteration of the cell membrane: substances that alter this structure, such as polymyxins, modify the permeability, allowing the exit of K ions and macromolecules, with the consequent lithic effect. (C) Inhibition of protein synthesis: for example, aminoglycosides bind to ribosomal subunits which lead to a wrong synthesis of proteins. (D) Alteration of nucleic acid synthesis: they produce inhibition of enzymes that are necessary for DNA replication, recombination and repair. For example, quinolones and fluoroquinolones inhibit the enzyme gyrase, which results in bacterial DNA fragmentation and subsequent cell death, and (E) Intermediate metabolism inhibitors: such as sulfonamides, which compete with p-aminobenzoic acid, blocking the synthesis of bacterial folic acid, inhibiting the growth and reproduction of the germ (Hosein, 2002; Kapoor et al., 2017).

The β -lactamics

Under this denomination a continuously increasing number of antimicrobials is grouped, whose origin dates back to 1928, when Alexander Fleming discovered a substance capable of inhibiting the growth of *S. aureus*. They form the most used group of clinical antimicrobials, among which penicillins, cephalosporins, carbapenemes and beta-lactamase inhibitors, among others (Gaynes, 2017). Within their molecular structure, they have in common the β -lactam ring, associated with another

thiazolidinic ring, forming the 6-aminopenicillanic acid responsible for the activity biological. He is associated with a side chain that gives the different antimicrobial and pharmacokinetic characteristics to the different antimicrobial derivatives (Konaklieva, 2014).

The action of β -lactams is developed by inhibiting the synthesis of the bacterial wall, acting in the final stage of the formation of peptidoglycan, called "transpeptidation." The β -lactams are analogs of a precursor amino acid of the peptidoglycan barrier, D-alanyl-D-alanine, therefore they compete for the active site of an enzyme called "Penicillin Binding Protein" (PLP), which acts at the cross-linking of peptidoglycan. Then the β -lactams covalently bind to the active site of the PLPs, which causes the irreversible inactivation of the enzyme, stopping the formation of peptidoglycan and producing osmotic lysis of the bacterial cell (Sarkar et al., 2017).

The introduction of a dimethoxyphenyl group to the side chain of penicillins gave rise to methicillin, which is resistant to enzymatic inactivation produced by beta-lactamases of *Staphylococcus aureus*. By adding an amino group to the side chain of the benzylpenicillins, the aminopenicillins were created, as a result of broadening the spectrum of action of the penicillins. Ampicillin, which belongs to this group, is effective against Gram-negative bacteria such as *Escherichia coli* and *Haemophilus influenzae* (Wright, 1999; Ashraf et al., 2015).

Bacterial resistance to β -lactam methicillin and ampicillin. The most

important mechanism of resistance to β -lactams is the production of β -lactamases, which consist of enzymes that hydrolyse the β -lactam ring of these antimicrobials and convert them into biologically inactive compounds. They are produced by Gram-positive and Gram-negative bacteria (Mediavilla and García-Lobo, 2004) and nowadays a great variety of β -lactamases is known that are divided into four molecular classes: 1) class A, represented by β -TEM type lactamases; 2) class B, represented by rare metalloenzymes; 3) class C, represented by cephalosporinases of enterobacteria, and 4) class D, represented by cloxacillinases.

The blaTEM gene encodes the most important β -lactamases in the development of resistance to β -lactams. The term TEM was named thanks to Temoniera, a patient from where the first bacterium with β -lactam resistance characteristics was isolated (Rawat and Nair, 2010). The most characteristic case of resistance by alteration of the sites of action is the resistance to methicillin in *S. aureus*. Methicillin binds with great affinity to *S. aureus* PBP 2 producing lysis of the bacteria. Isolates of methicillin resistant *S. aureus* strains are frequent, which, in addition to their normal PBP2, have a PBP2a, which has very low affinity for methicillin, being resistant to this antimicrobial (Stapleton and Taylor 2002; Rawat and Nair, 2010). This PBP2a can develop all the required cellular functions but does not allow the binding of β -lactams. Therefore, *S. aureus* methicillin resistant (SAMR) isolates are resistant to all β -lactams and frequently resistant to other classes of antimicrobials. PBP2a is encoded by the

mecA gene that is found in a long and mobile genetic element called the staphylococcus mec chromosomal cassette (CCS mec) (Baek et al., 2014).

Epidemiological surveillance of the bacterial resistance

As mentioned earlier, the use of antimicrobials implies the risk of inducing resistance in exposed bacteria, so it is necessary to take the appropriate measures to reduce the occurrence of this phenomenon. However, in order for these measures to be efficient, prior studies are necessary in regard to the type and quantity of antimicrobials used. In addition, the levels of bacterial resistance against specific drugs must be known, characterizing the bacteria and their resistance genes, which would result in the development of a constant surveillance system (Davies and Davies, 2010).

One of the international organizations that have taken great care to disseminate the appropriate use of antimicrobials has been the World Health Organization (WHO). In 1997, he made a report delivering a series of recommendations that should meet the countries to control the phenomenon of bacterial resistance in veterinary medicine (WHO, 2003).

In January 1999, the Pan American Health Organization (PAHO) developed a program for Latin American countries, in order to create an updated database to determine the magnitude and impact of antimicrobial resistance, proposing effective and dynamic measures of control, based on accurate data recording and standardized diagnostic procedures by national and

international reference laboratories (PAHO, 1999).

The WHO project for 2005 incorporated the surveillance of several species of medical interest of which we can mention *Campylobacter* spp.; Uropathogenic *E. coli*, *Salmonella* spp.; *Shigella* spp.; *Vibrio cholerae* O1 and O139 (enterobacteria), *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Haemophilus influenzae* and *Streptococcus pneumoniae*, plus β -hemolytic (pathogens acquired in the community); together with *S. aureus*, *Ps. aeruginosa*, *Acinetobacter* spp.; *E. faecium*, *E. faecalis* and other enterococci, *E. cloacae*, *K. pneumoniae*, *S. marcescens* and *Proteus* spp. (Nosocomial pathogens) (PAHO, 2005).

Molecular genetics techniques

The study and monitoring of these genes that give resistance has been carried out thanks to the implementation of molecular genetic techniques. These techniques allow to detect areas of interest in the genome of the microorganism.

Nucleic acid analysis methods have attracted the attention of the scientific world increasingly in recent years and are increasingly used in laboratories as routine diagnostic tests. Among the advantages of these techniques are: they do not need long bacterial isolation processes, are able to detect non-viable organisms, and even find alterations of the genetic material (Dwivedi et al., 2017).

The Polymerase Chain Reaction (PCR) consists in the in vitro synthesis of a white DNA sequence in a repetitive manner, thanks to the use of splitters (sequence of highly specific nucleotides)

that recognize small complementary sequences that flank the segment of the genome to be amplified. This was achieved through the use of Taq polymerase, an enzyme of the *Thermophilus aquaticus* bacterium that is capable of incorporating free nucleotides at the 3'-end of the splitter, generating copies of the white sequence exponentially, at short intervals of time and at elevated temperatures. It is characterized by its thermostability, high processivity and fidelity (Mullis and Faloona, 1987).

The PCR technique consists of the consecutive repetition of 3 basic steps, which together form a cycle. First, the white DNA is denaturated, generating two simple strands. This process is carried out at temperatures that vary between 90 and 96 °C. The second step is hybridization or "annealing" in which the splitters join it. The temperature of this stage is specific to each splitter. The third and final stage is the synthesis of DNA thanks to the action of a thermostable polymerase, which, starting from the starting points, "reads" the target strand, and joins nucleotides that will form the complementary strand to it. The result is two double strands of DNA, made up of the original strand, and the new strand formed, which will be the white strand or template of the next cycle. This process is repeated between 20 and 40 times (Hongbao, 2005). At the end of the series of cycles millions of copies of an area of the original DNA have been generated, which are visualized as bands when performing an electrophoresis, in which the DNA is separated according to its molecular weight and its negative electrical charge.

The DNA molecules are deposited in a polyacrylamide or agarose gel immersed in a buffer solution, which is subjected to an electric field. The concentration of the gel determines the density of the solution, and therefore, the speed with which the molecules of interest move. Indeed, the smaller the size of the reaction products, the more concentrated the gel should be used, thus, for diagnostic PCR, 2% agarose concentrations are generally used (Lee et al., 2012).

Contamination of the sample with external DNA is an important problem when performing the PCR test, since it leads to the amplification of non-specific genetic material that is irrelevant to the test. For this reason, in laboratories where this diagnostic methodology is practiced, precautionary measures must be taken to prevent the entry of contaminating DNA molecules, especially molecules that come from previous experiences to the one being carried out (Witt et al., 2009).

The detection of antimicrobial resistance genes in endemic strains allows establishing their relationship with mobile genetic elements and the epidemiological relevance that this phenomenon has, considering the mechanisms of genetic recombination that exist (Salyers and Amabile-Cuevas, 1997). At present, several researchers have followed the antimicrobial resistance genes, determining that the *bla*TEM and *mecA* genes have great epidemiological relevance and are detected more frequently in strains with phenotypic resistance characteristics (Tenover et al., 1994; Wichelhaus et al., 1999; Mediavilla and García-Lobo, 2004)

In Chile, there are no investigations aimed at detecting this type of genes in veterinary medicine, and studies carried out by the Institute of Public Health (ISP) and other entities expose an increase in resistance in antimicrobials using classical microbiology techniques (Pinto, 2002; Zuñiga et al., 2019).

In view of the latent risk associated with the transmission of bacteria between humans and animals, the increase in bacterial resistance, the absence of permanent surveillance programs and the high use of antimicrobials in Chile, this study sought to detect the genes that have been described most frequently in human medicine and that give antimicrobial resistance previously.

Methods and Materials

This research was carried out in the context of FIV project: "Detection of antibiotic and biocidal resistance genes in nosocomial bacteria isolated in the Veterinary Clinical Hospital of the University of Chile", developed in the Veterinary Microbiology Laboratory, belonging to the Department of Animal Preventive Medicine of the Faculty of Veterinary Sciences of the University of Chile.

Experimental design

From different units (hospitalization rooms, consultations, surgical pavilions and X-ray rooms) of the veterinary clinical hospitals of the University of Chile, 380 samples were taken from different surfaces (cages, work tables, furniture, anesthesia and x-rays machines).

The samples were collected using sterile torulates, which were immediately transferred to the

laboratory for processing, according to classical microbiology methodology, which is briefly described below: culture and bacterial isolation by dissemination or depletion, using the clock method, in media of special crops for these purposes. After the incubation of the sown plaques, the morphological and microscopic study of the colonies was carried out, which allowed us to know the type of bacteria developed, (coccus or bacilli, Gram positive or negative), which indicated if the colony was of interest for the study. If so, it was sown in a special culture medium, to ensure a completely pure development of that strain. Then, it was replicated in semi-transmitted agar (ceparium) and subsequently kept refrigerated until the bacterial strain was identified, using a commercial diagnostic kit (BBL Crystal®). The determination of antimicrobial susceptibility was performed using the Kirby Bauer plaque diffusion method, according to the standards of the National Committee for Clinical Laboratory Standard (NCCLS, 1997), using: Ampicillin (A), Amoxicillin+clavulanic acid (Amc), Oxacillin (Ox), Sulperazone (Sul), Gentamicin (G), Vancomycin (V), Tetracycline (T), Doxycycline (D), Enrofloxacin (Enr), Ciprofloxacin (Cip) and Sulfa/trimethoprine (Stx).

Samples

The bacterial strains of interest for this study met the following requirements: be bacteria described as nosocomial, Gram-positive coccus or Gram-negative bacilli, whose susceptibility profile by the Kirby Bauer method indicated sensitivity, intermediate sensitivity and/or resistance to ampicillin and

methicillin and in addition to being multi-resistant.

Sixty-seven bacterial strains were considered nosocomial: Gram-negative (n=28) and Gram-positive (n=39) and were obtained from the veterinary hospitals of the University of Chile (Bilbao and Faculty headquarters) between 2007 and 2008.

Obtaining bacterial DNA

Bacterial DNA extraction was performed using a commercial kit for extraction and purification (Genomic DNA Purification kit, Fermentas®), from cultures of 106 CFU /mL, concentration obtained with a McFarlane refractometer. Briefly, at 200 µL of bacterial culture, 400 µL of lysis solution was added, incubated for five minutes at 65 °C, manually homogenizing every 1.5 minutes. Immediately, 600 µL of chloroform was added by gently mixing and inverting five times. It was then centrifuged at 10,000 rpm for two minutes (Heraus Sepatech Biofuge®).

After centrifugation, the upper phase was collected in an Eppendorf tube and 800 µL of precipitation solution was added, mixed gently and centrifuged at 10,000 rpm for two minutes. The pellet obtained was resuspended by the addition of 100 µL of 1.2 M sodium chloride solution. To this mixture, 300 µL of cold ethanol was added and kept at -20 °C for ten minutes. Then, it was centrifuged at 10,000 rpm for four minutes, the supernatant was removed and resuspended in 100 µL of nuclease-free water (Winkler®). Finally, this DNA was used immediately to perform the PCR test or stored at 4 °C for no more than one month.

Gene detection by PCR technique

To carry out the PCR, a Apollo thermocycler (CLP, USA) was used. The references for utilized PCR protocols and primers are summarized in Table A.

PCR reaction Mix

A 2X PCR Master Mix kit (Fermentas®) was used, which contains thermostable polymerase, deoxynucleotide triphosphates (dNTPs), reaction buffer and MgCl₂. In a 0.2 mL Eppendorf tube, 12.5 µL of the Master Mix, 5 µL of each of the primers and 5 µL of the DNA

sample were added, obtaining a total volume of 27.5 µL. Homogenization was carried out using a vortex to ensure reagent mixing.

Results*Detection of bla_{TEM} gene by conventional PCR in Gram-negative bacteria*

The bla_{TEM} gene was detected in 2/14 of the sensitive strains, in 1/2 of the strains with intermediate sensitivity and in 8/11 of the resistant strains to ampicillin, determined by the Kirby-Bauer method (Figure 1; Table 1)

Table A. Primer sequences for detection of *mecA* and *Bla_{TEM}* genes

Gene	Primers	Size (bp), reference
<i>mecA</i>	5'-AAAATCGATGGTAAAGGTTGGC-3' 5'-AGTTCTGCAGTACCGGATTTGC-3'	533, Wichelhaus <i>et al.</i> , 1999
Bla _{TEM}	5'-TGGGTGCACGAGTGGGTTAC-3' 5'-TTATCCGCCTCCAT CCAGTC-3'	526, Tenover <i>et al.</i> , 1994




Fig 1. Gel de Agarosa al 2%. DNA fragments of 526 pb (bla_{TEM})

Table 1. Presence of *bla*_{TEM} gene in Gram-negative bacterial strains sorted according to specie and sensitivity to ampicillin

#	Specie	A	<i>bla</i> _{TEM}	#	Specie	A	<i>bla</i> _{TEM}
26	<i>P. agglomerans</i>	S	+	6	<i>E. cloacae</i>	R	+
27	<i>Ps. Aeruginosa</i>	S	+	16	<i>E. cloacae</i>	R	+
11	<i>E. coli</i>	IS	+	7	<i>E. coli</i>	R	+
13	<i>A. baumannii</i>	R	+	8	<i>E. coli</i>	R	+
1	<i>E. cloacae</i>	R	+	10	<i>E. coli</i>	R	+
				22	<i>E. coli</i>	R	+

A: ampicillin; S: sensitive; IS: intermediate sensitivity; R: resistant; (+): gene presence

Table 2. Presence of *bla*_{TEM} gene in Gram-positive bacterial strains sorted according to specie and sensitivity to ampicillin

#	Specie	A	<i>bla</i> _{TEM}	#	Especie	A	<i>bla</i> _{TEM}
58	<i>E. faecium</i>	S	+	35	<i>E. faecium</i>	R	+
62	<i>E. faecalis</i>	S	+	36	<i>E. faecium</i>	R	+
63	<i>E. durans</i>	S	+	37	<i>E. faecium</i>	R	+
64	<i>E. durans</i>	S	+	38	<i>E. faecium</i>	R	+
48	<i>E. faecium</i>	IS	+	49	<i>E. faecium</i>	R	+
53	<i>E. faecium</i>	IS	+	50	<i>E. faecium</i>	R	+
59	<i>E. faecium</i>	IS	+	51	<i>E. faecium</i>	R	+
43	<i>S. kloosi</i>	IS	+	52	<i>E. faecium</i>	R	+
29	<i>E. faecium</i>	R	+	57	<i>E. faecium</i>	R	+
30	<i>E. faecium</i>	R	+	67	<i>S. kloosi</i>	R	+
32	<i>E. faecium</i>	R	+	45	<i>St. Porcinus</i>	R	+
33	<i>E. faecium</i>	R	+	46	<i>M. sendentarius</i>	R	+

A: ampicillin; S: sensitive; IS: intermediate sensitivity; R: resistant; (+): gene presence


Fig 2 : Gel de Agarosa al 2%, DNA fragments of 533 pb (*mecA*)

Table 3. Presence of *mecA* gene in Gram-positive bacterial strains sorted according to specie and sensitivity to oxacillin

#	Specie	Ox	<i>mecA</i>
59	<i>E. faecium</i>	R	+
46	<i>M. sendentarius</i>	R	+
67	<i>S. kloosi</i>	R	+

Ox: oxacillin; R: resistant; (+): gene presence

Detection of blaTEM gene by conventional PCR in Gram-positive bacteria

The blaTEM gene was detected in 4/14 of the sensitive strains, in 4/5 of the strains with intermediate sensitivity and in 16/20 of the resistant strains to ampicillin, determined by the Kirby-Bauer method (Figure 1 and Table 2).

Detection of mecA gene by conventional PCR in Gram-positive bacteria

The mecA gene was detected in 3/32 of the resistant strains and not detected in 2 strains with intermediate sensitivity and neither in 5 sensitive strains to oxacillin, determined by the Kirby-Bauer method (Figure 2 and Table 3).

Discussion

Nosocomial bacteria have generated great concern - both in public and animal health - due to various characteristics: great ubiquity in hospital facilities, invasiveness in immunocompromised patients, high capacity to exchange and acquire genes that provide resistance and also a phenotypic development of multiresistance to different types of drugs, so that their treatment and control every day becomes more complicated (WHO, 2003; Almasaudi, 2018)

The increase in the number of conferences and publications conducted by human doctors and veterinarians in

recent times, promoting the rational use of antimicrobials and raising awareness on this issue, is a reflection of the concern generated by infections caused by multiresistant bacteria (Saloojee y Steenhoff, 2001; Sharma et al., 2018). For this reason, it has become necessary to use antimicrobials with a greater criterion, which encompasses both the clinical experience, and the theoretical framework in each therapeutic alternative applied, because currently such novel molecules as moxifloxacin, extended spectrum cephalosporins, Carbapenemic and monobacramic derivatives are ineffective when treating bacterial infections, especially nosocomial infections (DHQP, 2001; Waheed et al., 2016).

In Chile, there are studies in Human Medicine on this subject (García, 2003), unlike what happens in Veterinary Medicine, where there are no published data (Pinto, 2002). Therefore, it is essential to complete the information we have today in the country and to know the situation of hospital facilities at the University of Chile.

The data obtained in this report after subjecting the different infectious agents described as nosocomial, to the detection of genes that give them antimicrobial resistance, are consistent with those described in the literature

consulted (Wichelhaus et al., 1999; Haque et al., 2018).

Thus, after bacterial culture and isolation, the morphological and microscopic study of the colonies, the identification of the bacterial strains and finally the determination of antimicrobial susceptibility of the samples obtained from the Veterinary hospitals of the University of Chile, the strains were selected Bacterial of interest for this study. Observing the results, it is evident and it is important to highlight the high frequency of nosocomial bacteria found in the hospital environment, which have high levels of resistance for most of the studied antimicrobials. This reflects that our country is no stranger to the global problem of increased bacterial resistance, where nosocomial infections occur in 5% to 10% of all hospitalizations in Europe and North America, and in more than 40% of the hospitalizations in different parts of Asia, Latin America and South Africa (Raka et al., 2006; Rajabi et al., 2016; Ekapopphan et al., 2018).

There are many ways in which bacteria can acquire resistance genes, those mechanisms that involve transmissible resistance genes are of particular importance, mainly because they can spread rapidly (Alpuche and Daza, 2002, Sussmann et al., 2003; Bengtsson-Palme et al., 2018). It has been seen that more than 70% of the bacteria that produce nosocomial infections are resistant to one or more of the antibiotics commonly used in their treatment. This would explain the large number of bacterial strains in which we can find resistance genes (Muto et al., 2003; Li and Webster, 2018).

Considering the pressure of selection of the environment, and that a large part of these resistance mechanisms are transmissible among bacteria, it is feasible to think that an increase in the incidence of multiresistant nosocomial bacteria refractory to treatments is predictable (Poole, 2005; Cabrera et al., 2007; Aslam et al., 2018).

Some bacterial strains have intrinsic resistance to certain antimicrobials, others have progressively acquired resistance against others (CDC, 2008), such as vancomycin-resistant *Staphylococcus aureus* (SARV) that has developed great concern in medical practice, since vancomycin is an antimicrobial of shelter for the treatment of *Staphylococcus aureus* and there is a possibility that this bacterium has acquired resistance genes from vancomycin-resistant *Enterococcus* (ERV) (McGuinness et al., 2017).

Therefore, its finding or detection should be a constant concern in hospitals and clinics (CDC, 2008). The detection of the blaTEM gene in bacteria of the *Enterococcus* spp genus such as *E. faecalis* and *E. faecium* represents a high concern if we consider them to be of great clinical-epidemiological importance (Boerlin et al., 2001; Hanchi et al., 2018) and also have the highest frequency of isolation in the hospital precincts of the University of Chile. Additionally, in *E. faecalis* the detection of the blaTEM gene was performed in 17 samples, which means 44% of the Gram-positive strains analyzed.

It is very important to relate in a bacterial strain, the presence of a gene that gives resistance, detected by the PCR technique, with the profile of antimicrobial susceptibility observed by

the Kirby Bauer method, either sensitive, with intermediate sensitivity, and/or with resistance to a drug (Brown-Elliott et al., 2012).

In relation to the above, the expected result of this analysis would be to detect a resistance gene, in bacterial strains where resistance is observed for a certain drug by the method of Kirby Bauer, and in the same way, not to detect genes that give resistance, in sensitive strains. However, according to the results of this report, it was observed that a bacterial strain that exhibits resistance against a certain drug by the method of Kirby Bauer, may be negative for the detection of the respective resistance gene. Similarly, the presence of the gene involved in antimicrobial resistance was detected in a sensitive strain or with intermediate sensitivity to a drug (Rasheed et al., 2014; Urbaniak et al., 2018).

This phenomenon could be explained if we consider that the development of resistance is dependent on the mode and level of expression of the responsible gene, determined by the environmental conditions in which the particular bacterial strain is found. In addition, the absence of a gene in a bacterial strain does not limit the development of resistance against a certain drug, since the resistance mechanisms are very numerous and can use one, several combined or all (Chang et al., 2015; Munita and Arias, 2016; Hughes and Andersson, 2017).

In relation to the *mecA* gene, in this report it was possible to identify three positive bacterial strains, all resistant to oxacillin, a drug similar to methicillin, used to determine antimicrobial susceptibility using the Kirby-Bauer

method. Although the incidence of this gene proved to be low compared to the *blaTEM* gene, its presence is worrying mainly because the *mecA* gene is in a long and mobile genetic element called *Staphylococcus mec* chromosomal cassette (CCS *mec*), which It is easily acquired by bacterial strains in the hospital environment (Weese, 2005; Chen et al., 2014; Elhassan et al., 2015).

This suggests that there is a large number of bacteria with these resistance genes and in turn, highlights the concern and interest that should be given to this problem in the near future, mainly due to the high probability that these bacteria act as reservoirs of genes that They provide resistance and may emerge gradually as community pathogens and not only in hospital settings (Duquette and Nuttall, 2004; Beceiro et al., 2013).

A point of interest is the isolated *M. sendentarius* (46), *E. faecium* (59) and *S. kloosi* (67) because they have both the *blaTEM* gene and the *mecA* gene, which is possibly due to the ease of bacteria to transfer and acquire genes. In turn, in the hospital environment, bacterial populations are established that coexist under highly variable and demanding conditions, which expose them to various stress situations, which as a selective pressure force, has been the main cause of the emergence of highly resistant bacterial strains (Vali et al., 2008; Guzman-Prieto et al., 2016).

The results obtained suggest that conventional PCR is a technique that has great advantages in the identification of the genes under study. It is a fast method, since the process of obtaining DNA, amplification of the

same and electrophoresis can be carried out within 24 hours, which substantially decreases the time it takes to make a diagnosis using traditional methods; direct examination of colonies and culture (Wolcott, 1992; Garibyan and Avashia, 2013). The sensitivity of the method is high, because it allows to detect low concentrations of the DNA that you want to amplify and has a specificity high, especially determined by the sequence of the splitters used and the conditions of the white DNA strand. Additionally, our results are currently being complemented by the subsequent sequencing of the DNA fragments obtained, which will allow obtaining native positive controls (Lecomte et al., 2015; Kamal et al., 2017).

Finally, it is important that for the prevention and control of these bacteria, in the hospital enclosures at the University of Chile, necessary biosecurity measures are taken, where the fundamental steps to follow should be: have rigorous control measures regarding the use of antimicrobials, develop measures that prevent the transmission of pathogens that are already resistant (Alpuche and Daza, 2002; Raasch et al., 2018;) and finally generate an accurate data record, with the help of standardized diagnostic procedures by national and international reference laboratories (PAHO, 1999) complemented by the active search for the genes responsible for the resistance observed in antibiotics, antimicrobials and biocides in different species, analyzing their epidemiological relationship, in order to try to stop the increase of bacterial strains with multiresistance

characteristics, seeking to protect public and animal health .

Conclusions

It was possible to detect the blaTEM and mecA genes, which in nosocomial bacteria give more frequent resistance to ampicillin and methicillin, in samples obtained in veterinary hospitals of the University of Chile (Bilbao and Faculty headquarters) between 2007 and 2008.

In particular, the blaTEM gene was detected in 11/28 of the Gram-negative strains and in 24/39 of the Gram-positive bacteria. On the other hand, the mecA gene was detected in 3/39 of the Gram-positive strains.

Finally, the sequencing of the DNA fragments obtained by conventional PCR technique will confirm what is described in the existing literature.

References

- Almasaudi S (2018). Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features. Saudi journal of biological sciences, 25(3): 586-596.
- Alpuche C and Daza C (2002). Infecciones nosocomiales por bacterias Gram negativas resistentes a cefalosporinas de espectro extendido: asociación de dos peligrosos enemigos. Enf Infec Microbiol 22: 192-199.
- Alsan M and Klompas M (2010). Acinetobacter baumannii: An Emerging and Important Pathogen. J clin outc mang. 17(8): 363-369.
- Antonovics J, Wilson AJ, Forbes MR, Hauffe HC, Kallio ER, Leggett HC and Webster JP (2017). The evolution of transmission mode. Philosophical transactions of the Royal Society of London. Series B, Biological sciences,

- 372(1719), 20160083.
doi:10.1098/rstb.2016.0083
- Arkhipova IR, Yushenova IA (2019). Giant Transposons in Eukaryotes: Is Bigger Better?. *Genome biology and evolution*, 11(3): 906–918.
- Ashraf Z, Bais A, Manir MM and Niazi U (2015). Novel Penicillin Analogues as Potential Antimicrobial Agents; Design, Synthesis and Docking Studies. *PloS one*, 10(8): e0135293. doi:10.1371/journal.pone.0135293
- Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH and Baloch Z (2018). Antibiotic resistance: a rundown of a global crisis. *Infection and drug resistance*, 11: 1645–1658. doi:10.2147/IDR.S173867
- Baek KT, Gründling A, Mogensen RG, Thøgersen L, Petersen A, Paulander W and Frees D (2014). β -Lactam resistance in methicillin-resistant *Staphylococcus aureus* USA300 is increased by inactivation of the ClpXP protease. *Antimicrobial agents and chemotherapy*, 58(8), 4593–4603. doi:10.1128/AAC.02802-14
- Beceiro A, Tomás M, Bou G (2013). Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?. *Clinical microbiology reviews*, 26(2): 185–230.
- Bengtsson-Palme J, Kristiansson E and Larsson D (2018). Environmental factors influencing the development and spread of antibiotic resistance. *FEMS microbiology reviews*, 42(1): fux053. doi:10.1093/femsre/fux053
- Boerlin P, Eugster S, Gaschen F, Straub R and Schawalder P (2001). Transmission of opportunistic pathogens in a veterinary teaching hospital. *Vet Microbiol* 82: 347–359.
- Borneman E (2002). Bacterial infections: a response to recent ref. notes columns. <http://www.reefkeeping.com/translations/spanish/2002-05/eb/>
- Brown-Elliott BA, Nash KA, Wallace RJ (2012). Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. *Clinical microbiology reviews*, 25(3): 545–582.
- Cabrera C, Gomez R, Zuniga A (2007). La resistencia de bacterias a antibióticos, antisépticos y desinfectantes, una manifestación de los mecanismos de supervivencia y adaptación. *Colom. Med.* 38: 149–158.
- Cantón R and Morosini MI (2011). Emergence and spread of antibiotic resistance following exposure to antibiotics *FEMS Microbiology Reviews* 35: 977–991
- Casadevall A (2017). The Pathogenic Potential of a Microbe. *mSphere*, 2(1): e00015-17. doi:10.1128/mSphere.00015-17
- Center For Disease Control And Prevention (CDC) (2008). CDC/NHSN Surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. <http://www.cdc.gov/ncidod/dhqp/pdf/nnis/NosInfDefinitions.pdf>
- Chen FJ, Wang CH, Chen CY, Hsu YC, Wang KT (2014). Role of the *mecA* gene in oxacillin resistance in a *Staphylococcus aureus* clinical strain with a *pvl*-positive ST59 genetic background. *Antimicrobial agents and chemotherapy*, 58(2): 1047–1054.

- Davies J and Davies D (2010). Origins and evolution of antibiotic resistance. *Microbiology and molecular biology reviews*, 74(3): 417-433.
- Delavat F, Miyazaki R, Carraro N, Pradervand N, van der Meer JR (2017). The hidden life of integrative and conjugative elements. *FEMS Microbiology Reviews*, 41: 512-537.
- Division of Healthcare Quality Promotion (DHQP) (2001). Antimicrobial resistance prevention campaign. [presentación power point]. Atlanta, Georgia, United States of America. Center for Disease Control and Prevention (CDC). 63 diapositivas.
- Dwivedi M, Purohit P, Misra R, Pareek P, Goel A, Khattri S, Kumar K, Misra S, Sharma P (2017). Diseases and molecular Diagnostics: A step closer to precision medicine. *Ind Clin. Biochem* 32: 374 <https://doi.org/10.1007/s12291-017-0688-8>
- Ducel G, Fabry J and Nicolle L (2003). Prevención de infecciones nosocomiales GUIA PRÁCTICA. Segunda edición. Organización Mundial de la Salud. 65 p.
- Duquette R and Nuttall T (2004). Methicillin-resistant *Staphylococcus aureus* in dogs and cats: an emerging problem? *J Small Anim Pract.*, 45: 591-597.
- European Medicines Agency (EMA) (1999). Antibiotic Resistance in the European Union Associated with Therapeutic Use of Veterinary Medicines: Report and Qualitive Risk Assessment by Committe for Veterinary Medical Products. London 79 p.
- Elhassan MM, Ozbak HA, Hemeg HA, Elmekki MA and Ahmed LM (2015). Absence of the *mecA* Gene in Methicillin Resistant *Staphylococcus aureus* Isolated from Different Clinical Specimens in Shendi City, Sudan. *BioMed research international*, 2015, 895860. doi:10.1155/2015/895860
- Ekapopphan D, Srisutthakarn A, Moonarmart W, Buddhirongawatr R and Bangphoomi N (2018). Identification and antimicrobial susceptibility of microorganisms isolated from severe corneal ulcers of dogs in Thailand. *The Journal of veterinary medical science*, 80(8): 1259-1265.
- Emori G and Gaynes R (1993). An overview of nosocomial infections, including the role of the microbiology laboratory. *Clin Microbiol Rev* 6: 428-442.
- Fair RJ and Tor Y (2014). Antibiotics and bacterial resistance in the 21st century. *Perspectives in medicinal chemistry*, 6: 25-64.
- Faron ML, Ledeboer NA and Buchan B (2016). Resistance Mechanisms, Epidemiology, and Approaches to Screening for Vancomycin-Resistant *Enterococcus* in the Health Care Setting. *Journal of clinical microbiology*, 54(10), 2436-2447. doi:10.1128/JCM.00211-16
- Galler H, Feierl G, Petternel C, Reinthaler F, Haas D, Habib J, Kittinger C, Luxner J, Zarfel G (2018). Multiresistant Bacteria Isolated from Activated Sludge in Austria. *Int. J. Environ. Res. Public Health* 15: 479; doi:10.3390/ijerph15030479

- García P (2003). Resistencia bacteriana en Chile. *Rev Chil Infect* 20: S11-S23.
- Gaynes R (2017). The Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Use. *Emerging Infectious Diseases*, 23(5): 849–853.
- Ginawi I, Saleem M, Sigh M, Vaish AK, Ahmad I, Srivastava V and Abdullah A (2014). Hospital acquired infections among patients admitted in the medical and surgical wards of a non-teaching secondary care hospital in northern India. *Journal of clinical and diagnostic research* 8(2): 81–83.
- Guedon G, Libante V, Coluzzi C, Payot S and Leblond-Bourget N (2017). The Obscure World of Integrative and Mobilizable Elements, Highly Widespread Elements that Pirate Bacterial Conjugative Systems. *Genes*, 8(11): 337.
- Guggenbichler JP, Assadian O, Boeswald M and Kramer A (2011). Incidence and clinical implication of nosocomial infections associated with implantable biomaterials - catheters, ventilator-associated pneumonia, urinary tract infections. *GMS Krankenhaushygiene interdisziplinär*, 6(1): Doc18. doi:10.3205/dgkh000175
- Guzman-Prieto AM, van Schaik W, Rogers MR, Coque TM, Baquero F, Corander J and Willems RJ (2016). Global Emergence and Dissemination of Enterococci as Nosocomial Pathogens: Attack of the Clones?. *Frontiers in microbiology*, 7: 788.
- Hanchi H, Mottawea W, Sebei K and Hammami R (2018). The Genus *Enterococcus*: Between Probiotic Potential and Safety Concerns-An Update. *Frontiers in microbiology*, 9: 1791. doi:10.3389/fmicb.2018.01791
- Haque M, Sartelli M, McKimm J and Abu Bakar M (2018). Health care-associated infections - an overview. *Infection and drug resistance*, 11: 2321–2333.
- Hongbao M (2005). Development Application of Polymerase Chain Reaction (PCR). *The Journal of American Science*, 1(3): 1-47
- Hosein I, Hill D, Jenkins L and Magee J (2002). Clinical significance of the emergence of bacterial resistance in the hospital environment. *J Appl. Microbiol.* 92: 90S-97S.
- Jacoby G and Munoz-Price S (2005). The new β -lactamases. *N Engl J Med* 352: 380-391.
- Johnson J (2002). Nosocomial infections. *Vet Clin North Am Small Anim Pract.* 32: 1101-1126.
- Kamal IH, Wei ET, Yousuff CM and Bin NH (2017). Towards Multiplex Molecular Diagnosis- A Review of Microfluidic Genomics Technologies. *Micromachines* 8(9): 266.
- Kim B-N, Woo J-H, Ryu J and Kim Y (2003). Resistance to extended-spectrum cephalosporins and mortality in patients with *Citrobacter freundii* bacteremia. *Infection* 31: 202-207.
- Konaklieva MI (2014). Molecular Targets of β -Lactam-Based Antimicrobials: Beyond the Usual Suspects. *Antibiotics* (Basel, Switzerland), 3(2): 128–142.
- Lecomte, E., Tournaire, B., Cogné, B., Dupont, J. B., Lindenbaum, P., Martin-Fontaine, M., Léger, A. 2015. Advanced Characterization of DNA Molecules in rAAV Vector

- Preparations by Single-stranded Virus Next-generation Sequencing. Molecular therapy. Nucleic acids, 4(10), e260. doi:10.1038/mtna.2015.32
- Lee PY, Costumbrado J, Hsu CY and Kim Y (2012). Agarose gel electrophoresis for the separation of DNA fragments. Journal of visualized experiments: JoVE, (62): 3923.
- Li B and Webster TJ (2018). Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. Journal of orthopaedic research : official publication of the Orth. Research Society, 36(1): 22-32.
- Lui P, Hall L and Livermore D (1992). Survey of the prevalence of beta-lactamases among 1000 Gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother, 30: 429-447.
- McDonnell G and Russell AD (2001). Antiseptics and Disinfectants: Activity, Action, and Resistance. Clinical Microbiology Reviews 14(1): 227.
- McGuinness WA, Malachowa N and DeLeo FR (2017). Vancomycin Resistance in Staphylococcus aureus. The Yale journal of biology and medicine, 90(2): 269-281.
- Mediavilla A and García-Lobo J (2004). Antibióticos β -lactámicos. In: Flores, J.; Armijo, J.A.; Mediavilla, A. Farmacología Humana, 4.a edición. Masson, S.A. Barcelona (España). Pp. 1105-1128.
- Mehrad B, Clark NM, Zhanel GG and Lynch J (2015). Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest, 147(5): 1413-1421.
- Mehta Y, Gupta A, Todi S, Myatra S, Samaddar DP, Patil V and Ramasubban S (2014). Guidelines for prevention of hospital acquired infections. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine, 18(3): 149-163.
- Milatovic D and Bravendy I (1987). Development of resistance during antibiotic therapy. Eur J Clin Microbiol 6: 234-244.
- Morfin R, Donis J, Arredondo J, Soriano D, Hermida C, Heredia J, Esparza S and Rodriguez E (2002). Infecciones nosocomiales por bacterias grampositivas multirresistentes: La actividad de nuevos antimicrobianos. Enf. Infec y Micro. 22: 55-61.
- Mullis K and Faloona F (1987). Specific synthesis of DNA in Vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155: 335-350.
- Munita J and Arias C (2016). Mechanisms of Antibiotic Resistance. Microbiology spectrum, 4(2), 10.1128/microbiolspec.VMBF-0016-2015.
- Murni I, Duke T, Triasih R, Kinney S, Daley AJ and Soenarto Y (2013). Prevention of nosocomial infections in developing countries, a systematic review. Paediatr Int Child Health. 33(2): 61-78.
- Muto C, Jernigan J, Ostrowsky B, Richet H, Jarvis W, Boyce J and Farr B (2003). SHEA Guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and

- Enterococcus. Infect Control Hosp Epidemiol. 24: 362-386.
- National Committee for Clinical Laboratory Standards (1997). Performance standards for antimicrobial disk susceptibility test. Approved standards. NCCLS document. National Committee for Clinical Laboratory Standards, Wayne, Pa.
- Nikaido H (2009). Multidrug resistance in bacteria. Annual review of biochemistry, 78: 119-146.
- Organizacion Mundial De La Salud (OMS). (2003). Epidemiología de las infecciones nosocomiales. cap.1. In: Prevención de las infecciones nosocomiales.<
<http://www.who.int/csr/resources/publications/drugresist/PISpanish3.pdf>>
- Organización Panamericana De La Salud (OPS), División De Prevención Y Control De Enfermedades, Programa De Enfermedades Transmisibles (1999). Prevención y control de la Resistencia a los antimicrobianos en las Américas: Plan estratégico de vigilancia de la resistencia a los antibióticos. 45p.
- Organización Panamericana De La Salud (OPS). (2005). Informe anual de la Red de Monitoreo/Vigilancia de la resistencia a los antibióticos - 2004-. Brasilia, Brasil. 115p.
- Pascual A, Rodriguez-Baño J, Ramirez De Arellano E, Mola J, Martinez-Martinez L (2001). Sensibilidad disminuida a vancomicina en cepas isogénicas de Staphylococcus aureus aisladas del mismo paciente. Med. Clin. 117: 416-418.
- Peleg A, Seifert H and Paterson D (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin Microbiol Rev. 21: 538-582.
- Peters L, Olson L, Khu D, Linnros S, Le NK, Hakan H, Hoang N, Tran D and Larsson M (2019). Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam. PLoS ONE 14(5): e0215666.
- Peterson E and Kaur P (2018). Antibiotic Resistance Mechanisms in Bacteria: Relationships Between Resistance Determinants of Antibiotic Producers, Environmental Bacteria, and Clinical Pathogens. Frontiers in microbiology, 9, 2928. doi:10.3389/fmicb.2018.02928
- Pinto M (2002). Resistencia antimicrobiana en Chile hoy. Rev Chil Infect. 19: 213-218.
- Poole K (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chem.. 56: 20-51.
- Prestinaci F, Pezzotti P and Pantosti A (2015). Antimicrobial resistance: a global multifaceted phenomenon. Pathogens and global health, 109(7), 309-318. doi:10.1179/2047773215Y.0000000030
- Rajabi M, Abdar ME, Rafiei H, Aflatoonia MR and Abdar ZE (2015). Nosocomial Infections and Epidemiology of Antibiotic Resistance in Teaching Hospitals in South East of Iran. Global journal of health sci., 8(2): 190-197.
- Raka L, Zoutman D, Mulliqi G, Krasniqi S, Dedushaj I, Raka N, Ahmeti S, Shala M, Vishaj A and Elezi Y (2006). Prevalence of nosocomial infections

- in high-risk units in the University Clinical Center of Kosova. *Infect Control Hosp Epidemiol*. 27: 421-423.
- Rasheed MU, Thajuddin N, Ahamed P, Teklemariam Z and Jamil K (2014). Antimicrobial drug resistance in strains of *Escherichia coli* isolated from food sources. *Revista do Instituto de Medicina Tropical de Sao Paulo*, 56(4): 341-346.
- Rawat D and Nair D (2010). Extended-spectrum β -lactamases in Gram Negative Bacteria. *Journal of global infectious diseases*, 2(3): 263-274.
- Revelas A (2012). Healthcare - associated infections: A public health problem. *Nigerian medical journal: journal of the Nigeria Medical Association*, 53(2): 59-64.
- Rosenthal V, Maki D, Salomao R, Alvarez-Moreno C, Mehta Y, Higuera F, Cuellar L, Arikan O, Abouqal R and Leblebicioglu H (2006). Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. *Ann. Intern. Med.* 145: 582-591.
- Rousham EK, Unicomb L and Islam MA (2018). Human, animal and environmental contributors to antibiotic resistance in low-resource settings: integrating behavioural, epidemiological and One Health approaches. *Proceedings. Biological sciences*, 285(1876), 20180332.
- Saloojee H and Steenhoff A (2001). The health professional's role in preventing nosocomial infections. *Postgrad. Med. J.* 77: 16-19.
- Salyers A and Amabile-Cuevas C (1997). Why Are Antibiotic Resistance Genes So Resistant to Elimination? *Antimicrob Agents Chemother*, 41, 2321-2325.
- Sarkar P, Yarlagadda V, Ghosh C and Haldar J (2017). A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. *MedChemComm*, 8(3), 516-533
- Sharma C, Rokana N, Chandra M, Singh BP, Gulhane RD, Gill J and Panwar H (2018). Antimicrobial Resistance: Its Surveillance, Impact, and Alternative Management Strategies in Dairy Animals. *Frontiers in veterinary science*, 4, 237. doi:10.3389/fvets.2017.00237
- Stapleton P and Taylor P (2002). Methicillin resistance in *Staphylococcus aureus*: mechanisms and modulation. *Science progress*, 85(Pt 1): 57-72.
- Stickler D (2002). Susceptibility of antibiotic-resistant Gram-negative bacteria to biocides: a perspective from the study of catheter biofilms. *J Appl Microbiol* 92: 163S-170S.
- Stokes H and Hall R (1989). A novel family of potentially mobile genetics DNA elements encoding site-specific gene-integration functions: integrons. *Mol Microbiol* 3: 1669-1683.
- Sussmann O, Johnson J, Harris P, Furuno J, Perencevich E and Morris J (2003). Assessing risk for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in *Enterococcus faecium*. *The Lancet* 3: 241-249.
- Sydnor E and Perl T (2011). Hospital epidemiology and infection control in acute-care settings. *Clin. Micro. Rev.*, 24(1): 141-173
- Tenover F, Huang M, Rasheed J and Persing D (1994). Development of

- PCR Assay To Detect Ampicillin Resistance Genes in Cerebrospinal Fluid Samples Containing *Haemophilus influenzae*. *J Clin Microbiol.*, 32: 2729-2737.
- Tsang J (2018). Bacterial plasmid addiction systems and their implications for antibiotic drug development. *Postdoc journal: a journal of postdoctoral research and postdoctoral affairs*, 5(5): 3-9.
- Urbaniak C, Sielaff AC, Frey KG, Allen JE, Singh N, Jaing C and Venkateswaran K (2018). Detection of antimicrobial resistance genes associated with the International Space Station environmental surfaces. *Scientific reports*, 8(1): 814.
- Vali L, Davies S, Lai L, Dave J, Amyes S (2008). Frequency of biocide resistance genes, antibiotic resistance and the effect of chlorhexidine exposure on clinical methicillin-resistant *Staphylococcus aureus* isolates. *J Antimicrob Chemo.*, 61: 524-532.
- Van Duin D and Paterson DL (2016). Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned. *Infect. disease clinics of North America*, 30(2): 377-390.
- Waheed N, Azeez H and Abachi F (2016). Combinations of Carbapenem with Fluoroquinolones or 1,3,4 - Oxadiazole-2 -Thione Derivatives as New Broad Spectrum Bactericidal Antibiotics for Ophthalmic Preparation. *J Drug Design and Med. Chem.* 2: 47-50.
- Weese J (2005). Methicillin-Resistant *Staphylococcus aureus*: An Emerging Pathogen in Small Animals. *J. Amer. Anim. Hosp. Assoc.* 41: 150-157.
- Wichelhaus T, Kern S, Schafer V and Brade V (1999). Rapid Detection of Epidemic Strains of Methicillin-Resistant *Staphylococcus aureus*. *J Clin Microbiol.*, 37: 690-693.
- Wilkins B and Frost L (2002). Mechanisms of gene exchange between bacteria. In: SUSSMAN, M. *Molecular Medical Microbiology*. Barcelona. España. Academic Press. pp. 335-400.
- Witt N, Rodger G, Vandesompele J, Benes V, Zumla A, Rook GA and Huggett JF (2009). An assessment of air as a source of DNA contamination encountered when performing PCR. *Journal of biomolecular techniques : JBT*, 20(5): 236-240.
- Wolcott M (1992). Advances in nucleic acid-based detection methods. *Clin. Microbiol. Rev.*, 5: 370-386.
- Zeng X and Lin J (2013). Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria. *Front. Microbiol.* 4:128.
- Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, Karlowsky JA (2001). Review of macrolides and ketolides: focus on respiratory tract infections. *Drugs* 61(4): 443-98.
- Zuniga B, Jara MA, Mosnaim A and Navarro C (2019). Detection of resistance *mecA* gene in Gram positive bacteria described as nosocomial. *Am J Biomed Sci & Res.* 4(5). DOI: 10.34297/AJBSR.2019.04.000831
